Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting
Author:
Publisher
Elsevier BV
Subject
Cancer Research
Reference88 articles.
1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N. Engl. J. Med.,2010
2. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N. Engl. J. Med.,2015
3. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial;Motzer;J. Clin. Oncol.,2015
4. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014
5. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial;Younes;Lancet Oncol.,2016
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors;Molecular Cancer;2023-08-15
2. Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects;Frontiers in Pharmacology;2022-09-01
3. MAOI Antidepressants: Could They Be a Next-Generation ICB Therapy?;Frontiers in Immunology;2022-03-14
4. Recent advances in targeted nanomedicine as promising antitumor therapeutics;Drug Discovery Today;2020-12
5. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications;Journal of Experimental & Clinical Cancer Research;2020-02-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3